PROPHASE LABS INC (PRPH) Stock Price & Overview
NASDAQ:PRPH • US74345W1080
The current stock price of PRPH is 0.3626 USD. Today PRPH is down by -18.97%. In the past month the price decreased by -73.2%. In the past year, price decreased by -95.64%.
PRPH Key Statistics
- Market Cap
- 15.947M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -23.40
- Dividend Yield
- N/A
PRPH Stock Performance
PRPH Stock Chart
PRPH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PRPH. When comparing the yearly performance of all stocks, PRPH is a bad performer in the overall market: 99.84% of all stocks are doing better.
PRPH Earnings
PRPH Forecast & Estimates
For the next year, analysts expect an EPS growth of 97.56% and a revenue growth 64.06% for PRPH
PRPH Groups
Sector & Classification
PRPH Financial Highlights
Over the last trailing twelve months PRPH reported a non-GAAP Earnings per Share(EPS) of -23.4. The EPS decreased by -138.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.22% | ||
| ROE | -777.79% | ||
| Debt/Equity | 0.74 |
PRPH Ownership
PRPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.85 | 951.275B | ||
| JNJ | JOHNSON & JOHNSON | 20.83 | 584.618B | ||
| MRK | MERCK & CO. INC. | 22.63 | 289.542B | ||
| PFE | PFIZER INC | 8.98 | 152.449B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.57 | 123.471B | ||
| ZTS | ZOETIS INC | 17.29 | 51.652B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.87 | 26.443B | ||
| VTRS | VIATRIS INC | 5.67 | 16.373B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.76 | 11.902B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.414B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.72B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.704B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.59 | 4.169B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRPH
Company Profile
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Company Info
IPO: 1984-01-16
PROPHASE LABS INC
711 Stewart Ave, Suite 200, Garden City
New York City NEW YORK 11530 US
CEO: Ted Karkus
Employees: 96
Phone: 12153450919
PROPHASE LABS INC / PRPH FAQ
What does PROPHASE LABS INC do?
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
What is the current price of PRPH stock?
The current stock price of PRPH is 0.3626 USD. The price decreased by -18.97% in the last trading session.
What is the dividend status of PROPHASE LABS INC?
PRPH does not pay a dividend.
How is the ChartMill rating for PROPHASE LABS INC?
PRPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is PROPHASE LABS INC (PRPH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRPH.
When does PROPHASE LABS INC (PRPH) report earnings?
PROPHASE LABS INC (PRPH) will report earnings on 2026-03-30, after the market close.